跳至主要内容
临床试验/EUCTR2011-002563-23-LT
EUCTR2011-002563-23-LT进行中(未招募)不适用

A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease - SPRING

MedImmune Limited0 个研究点目标入组 300 人开始时间: 2011年12月16日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age 45 through 75 years.
  • - Predicted (GOLD stage II, III, and IV) at screening.
  • - History of previous AECOPD 12 months prior to screening Clinically stable and free from an AECOPD for 8 weeks prior to Day 1.
  • - Current smoker or ex-smoker with a tobacco history of = 10 pack-years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 230
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • - Past or present disease or disorder,
  • - Significant or unstable ischemic heart disease, etc
  • - Known history of allergy or reaction to any component of the IMP
  • - Past or current malignancy within the past 5 years
  • - Subjects have had a chest x-ray or CT scan suggestive of malignancy or tuberculosis (TB).
  • - Use of immunosuppressive medication receipt of any biologic agent

研究者

相似试验

进行中(未招募)
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855
EUCTR2011-002563-23-PLMedImmune Limited300
进行中(未招募)
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary Disease
EUCTR2011-002563-23-HUMedImmune Limited300
进行中(未招募)
1 期
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary Disease
EUCTR2011-002563-23-GBMedImmune Limited324
进行中(未招募)
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2011-002563-23-LVMedImmune Limited300
进行中(未招募)
1 期
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary Disease
EUCTR2011-002563-23-CZMedImmune Limited300